Literature DB >> 10588254

Sotradecol (sodium tetradecyl sulfate) injection of orbital lymphangioma.

T H Wojno1.   

Abstract

PURPOSE: To describe the results of intralesional injection of the sclerosing agent sodium tetradecyl sulfate in patients with lymphangioma.
METHODS: Three patients (one child and two adults) were treated.
RESULTS: Two patients had improvement in the size of the lymphangioma, although the result was short-lived in one instance. Minimal change was noted in the third patient. Two patients had transient edema and ecchymosis, and one patient had a mild allergic reaction to the injected solution.
CONCLUSIONS: Sodium tetradecyl sulfate may be a useful therapeutic option for some patients with eyelid or orbital lymphangioma, particularly if a previous operation has not been performed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588254     DOI: 10.1097/00002341-199911000-00013

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  4 in total

1.  Navigation-assisted sclerotherapy of orbital venolymphatic malformation: a new guidance technique for percutaneous treatment of low-flow vascular malformations.

Authors:  Ulrike Ernemann; Carsten Westendorff; Dirk Troitzsch; Jürgen Hoffmann
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

2.  Direct puncture and sclerotherapy with sotradecol ((r)) . Orbital lymphatic malformations.

Authors:  P A Svendsen; G Wikholm; M Rodriguez; P Enoksson; L Frisén; K Strömland; S Seregard
Journal:  Interv Neuroradiol       Date:  2001-10-15       Impact factor: 1.610

3.  Sclerosing therapy for orbital lymphangioma using sodium tetradecyl sulfate.

Authors:  Anuchit Poonyathalang; Pisit Preechawat; Pakorn Jiarakongmun; Sirintara Pongpech
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

4.  Intralesional injection of OK-432 for vision-threatening orbital lymphangioma.

Authors:  Jin Sook Yoon; Jung Bum Choi; Sung Joo Kim; Sang Yeul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02-14       Impact factor: 3.535

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.